Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 67 (12), 2058-2059

Ultra-widefield Angiographic Imaging of Albumin-Bound Paclitaxel-Induced Cystoid Macular Edema

Affiliations

Ultra-widefield Angiographic Imaging of Albumin-Bound Paclitaxel-Induced Cystoid Macular Edema

Junhyuck Lee et al. Indian J Ophthalmol.

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Ultra-widefield color fundus photography and optical coherence tomography at the patient's initial visit. (a) Color fundus photography revealed no abnormality in either eye. (b) Optical coherence tomography revealed cystoid macular edema in both eyes
Figure 2
Figure 2
Ultra-widefield fluorescein angiography and indocyanine green angiography at the patient's initial visit. (a) Late-phase ultra-widefield (UWF) fluorescein angiography (FA) of the fovea showed minimal leakage in the right eye and no leakage in the left eye. (b) Late-phase UWF FA of the peripheral retina revealed no abnormal findings in either eye. (c) Late-phase UWF ICGA showed no abnormal findings at the fovea in either eye. (d) Late-phase UWF ICGA revealed no abnormal findings, including choroidal vascular hyperpermeability, large vessel dilation, or vortex ampullae obstruction
Figure 3
Figure 3
Follow-up optical coherence tomography image of the patient after withdrawal of paclitaxel. (a) Optical coherence tomography (OCT) 2 weeks after cessation of the paclitaxel revealed disappearance of the cystoid macular edema. (b) OCT image at 3 months revealed no intraretinal fluid in either eye

Similar articles

See all similar articles

References

    1. Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol. 2007;125:709–10. doi: 10.1001/archopht.125.5.709. - PubMed
    1. Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol. 2008;126:1605–6. doi: 10.1001/archopht.126.11.1605. - PubMed
    1. Baskin DE, Garg SJ. Abraxane-induced cystoid macular edema refractory to concomitant intravenous bevacizumab? Can J Ophthalmol. 2011;46:200–1. doi: 10.3129/i11-001. - PubMed
Feedback